The lawsuit against former Theranos chief operating officer Sunny Balwani continued on Friday with two strategies exposed – one trying to portray him as an active manager and the other as a wealthy observer.
As Balwani’s defense team tried to convince the jury that CEO Elizabeth Holmes and a team of scientists made the decisions about the company, the prosecution took several lab directors to the stand to say Balwani was makes him an active manager.
On Friday, Dr. Adam Rosendorff told the jury that Balwani was involved in the day-to-day running of the Theranos lab, bolstering the prosecution’s claim that he was active in what happened at medical device company Palo Alto. , now bankrupt.
“It’s the fact that each of the witnesses is part of the basis of painting the picture that, yes, Elizabeth Holmes was the CEO, and ultimately she was involved in the decision-making, but as far as the day-to-day operations, it was Sunny Bawani, who was not just an investor, but was the OPS guy,” said Aid Aron Solomon, legal analyst at Esquire Digital.
Balwani’s defense wanted to tell the jury that another lab Dr. Rosendorff worked for, San Francisco-based uBiome, which sat as the SEC sued its founders, but the judge did not allow it, so they only heard of Theranos.
“Every lab director, everyone who is able to take the stand and talk about the degree of control Sunny Balwani had over operations, it becomes a cumulative thing,” Solomon said. “These witnesses represent building blocks in the case against Sunny Balwani.”
Doctor Rosendorff will be back at the helm next week. It is likely to be followed by patients testifying that they got inaccurate results from Theranos blood test machines.